Gerstein HZ, Miller ME, Byington RP, et al
The most frequent gastrointestinal side effects include: Nausea and vomiting : Very common, typically most pronounced during dose escalation Diarrhoea : Common to very common, though usually mild to moderate Constipation : Can occur due to delayed gastric emptying and reduced gut motility Abdominal pain and discomfort : Common Dyspepsia and gastro-oesophageal reflux : May worsen in susceptible individuals Other important adverse effects include: Gallbladder disorders : Cholelithiasis and cholecystitis have been reported, particularly with weight loss Dehydration and acute kidney injury : May occur secondary to severe gastrointestinal symptoms Hypoglycaemia : Risk increases when used with insulin or sulfonylureas, which may require dose adjustment Current limited evidence does not suggest an increased risk of inflammatory bowel disease (IBD) flares with GLP-1 agonists, though more data are needed

1 pre-filled multi-dose pen Full instructions Tamper-proof verification sticker 8 sterile needles Combined BPC-157 and TB-500 multi-dose injection pen
The concentration of your compounded semaglutide also matters
GLP-1 medicines decrease the rates of complications associated with obesity and T2D
Log each dose, track your progress, and export your schedule